Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE (GSK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

GlaxoSmithKline And University Of Nottingham Establish Research Center

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:46am CEST

Drug maker GlaxoSmithKline PLC (>> GlaxoSmithKline plc) and the University of Nottingham said Thursday that they formalized a collaboration to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to construct an innovative carbon neutral sustainable chemistry laboratory.

MAIN FACTS:

-The Laboratory for Sustainable Chemistry is being supported by a GBP12 million grant from Glaxo.

-Shares at 0829 GMT, down 10 pence, or 0.71%, at 1,403.5 pence valuing the company at GBP71.28 million.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; [email protected]

Stocks mentioned in the article : GlaxoSmithKline plc
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE -0.11% 1507.6 Delayed Quote.13.18%
GLAXOSMITHKLINE -0.70% 17.208 Delayed Quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
07:30aGLAXOSMITHKLINE : GSK May Look at Merger Options for Indian Unit -The Economic T..
DJ
05/23Why the world needs more than one Ebola vaccine
RE
05/22ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/..
AQ
05/21GLAXOSMITHKLINE : GSK receives US approval of Arnuity Ellipta for use in childre..
PU
05/21EU Approves GlaxoSmithKline JV's Juluca HIV Treatment
DJ
05/21GLAXOSMITHKLINE : ViiV granted EU marketing authorisation for Juluca
PU
05/21GLAXOSMITHKLINE : Nucala (mepolizumab) study reports long-term safety data, cons..
PU
05/18GLAXOSMITHKLINE : Regulators flag possible birth defect link to GSK's HIV drug
RE
05/18Hikma reaffirms full-year revenue forecast, cites better generics business
RE
05/18GSK bets on lift from new lung drugs ahead of Advair's last gasp
RE
More news
News from SeekingAlpha
05/23High Rates And Inflation Could Pose A Systemic Risk To Biotech 
05/22YOUR DAILY PHARMA SCOOP : Sesen Bio Presents Vicinium Data, UroGen's Mitogel Dat.. 
05/22Entera Bio Re-Enters IPO Process 
05/22CORE BIOTECH BUYS #16 : Taking Advantage Of Weakness To Add To Conviction Ideas 
05/21FDA OKs expanded use for Glaxo's asthma med Arnuity Ellipta 
Financials ( GBP)
Sales 2018 29 826 M
EBIT 2018 8 109 M
Net income 2018 3 804 M
Debt 2018 18 280 M
Yield 2018 5,31%
P/E ratio 2018 19,41
P/E ratio 2019 16,34
EV / Sales 2018 3,12x
EV / Sales 2019 3,01x
Capitalization 74 766 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 15,5  GBP
Spread / Average Target 3,0%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE13.18%100 378
JOHNSON & JOHNSON-11.45%329 663
PFIZER-1.16%208 947
NOVARTIS-6.55%201 263
ROCHE HOLDING LTD.-8.90%194 670
MERCK AND COMPANY3.87%157 248